Investor Presentation Full Year 2021
102
Investor presentation
Full year 2021
Region China at a glance.
Region China
Million
250
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
DKK
billion
25
8%
21%
Full year 2021
Sales
(mDKK)
Growth²
100%
Total GLP-13
1,847
73%
200
20
GLP-1
20
Long-acting insulin4
2,080
38%
80%
I
62%¹
Premix insulin5
5,224
5%
150
15
60%
Fast-acting insulin6
2,288
7%
Insulin
Human insulin
212
100
197
10
163
2,692
(1%)
110
13%1
40%
Total insulin
12,284
8%
Other Diabetes care?
50
1,432
5
20%
(10%)
8%1
OAD
Diabetes care
15,563
11%
0
2019
0
0%
Nov
2030
2045
2016
Nov
2021
Obesity care (SaxendaⓇ)
Diabetes & Obesity care
61
N/A
15,624
11%
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
-OAD MS
Biopharm³
395
(11%)
Total
16,109
11%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition 2000 and
Diabetes Atlas 9th Edition 2019
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Nov 2021: Novo Nordisk 49%, Sanofi
17%, Gan & Lee 13% and Eli Lilly 8%; Competitor GLP-1 value market shares, as of
Nov 2021: Novo Nordisk 74% and Eli Lilly 18%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, Nov 2021 value
figures
2 At constant exchange rates; 3 Comprises VictozaⓇ and OzempicⓇ;
Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 5 Comprises NovoMix® and
RyzodegⓇ: 6 Comprises NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8
Comprises primarily NovoSeven®, Novo Eight® and NorditropinⓇ
4View entire presentation